Home  |  Contact

UniProtKB/Swiss-Prot Q8IUC6: Variant p.Ser186Leu

TIR domain-containing adapter molecule 1
Gene: TICAM1
Variant information

Variant position:  186
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Serine (S) to Leucine (L) at position 186 (S186L, p.Ser186Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and polar (S) to medium size and hydrophobic (L)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In IIAE6; no effect on IFNB induction.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  186
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  712
The length of the canonical sequence.

Location on the sequence:   PPSSALPSGTRSLPRPIDGV  S DWSQGCSLRSTGSPASLASN
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PPSSALPSGTRSLPRPIDGVSDWSQGCSLRSTGSPASLASN

Mouse                         QPPSASPAVTRSQPRPID-TPDWSWGHTLHSTNSTASLASH

Bovine                        PPSSASLSRTRSDPRPIEHLSGWSTACSLRSTGSPASLGSN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 712 TIR domain-containing adapter molecule 1
Site 190 – 190 (Microbial infection) Cleavage; by viral HAV 3CD
Mutagenesis 190 – 190 Q -> A. No effect on cleavage by Seneca Valley virus protease 3C.
Mutagenesis 190 – 190 Q -> R. No cleavage by HAV 3CD.
Mutagenesis 202 – 202 S -> A. Decreased interaction with IRF3.


Literature citations

Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency.
Sancho-Shimizu V.; Perez de Diego R.; Lorenzo L.; Halwani R.; Alangari A.; Israelsson E.; Fabrega S.; Cardon A.; Maluenda J.; Tatematsu M.; Mahvelati F.; Herman M.; Ciancanelli M.; Guo Y.; AlSum Z.; Alkhamis N.; Al-Makadma A.S.; Ghadiri A.; Boucherit S.; Plancoulaine S.; Picard C.; Rozenberg F.; Tardieu M.; Lebon P.; Jouanguy E.; Rezaei N.; Seya T.; Matsumoto M.; Chaussabel D.; Puel A.; Zhang S.Y.; Abel L.; Al-Muhsen S.; Casanova J.L.;
J. Clin. Invest. 121:4889-4902(2011)
Cited for: VARIANT IIAE6 LEU-186;

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
Zhang Q.; Bastard P.; Liu Z.; Le Pen J.; Moncada-Velez M.; Chen J.; Ogishi M.; Sabli I.K.D.; Hodeib S.; Korol C.; Rosain J.; Bilguvar K.; Ye J.; Bolze A.; Bigio B.; Yang R.; Arias A.A.; Zhou Q.; Zhang Y.; Onodi F.; Korniotis S.; Karpf L.; Philippot Q.; Chbihi M.; Bonnet-Madin L.; Dorgham K.; Smith N.; Schneider W.M.; Razooky B.S.; Hoffmann H.H.; Michailidis E.; Moens L.; Han J.E.; Lorenzo L.; Bizien L.; Meade P.; Neehus A.L.; Ugurbil A.C.; Corneau A.; Kerner G.; Zhang P.; Rapaport F.; Seeleuthner Y.; Manry J.; Masson C.; Schmitt Y.; Schlueter A.; Le Voyer T.; Khan T.; Li J.; Fellay J.; Roussel L.; Shahrooei M.; Alosaimi M.F.; Mansouri D.; Al-Saud H.; Al-Mulla F.; Almourfi F.; Al-Muhsen S.Z.; Alsohime F.; Al Turki S.; Hasanato R.; van de Beek D.; Biondi A.; Bettini L.R.; D'Angio' M.; Bonfanti P.; Imberti L.; Sottini A.; Paghera S.; Quiros-Roldan E.; Rossi C.; Oler A.J.; Tompkins M.F.; Alba C.; Vandernoot I.; Goffard J.C.; Smits G.; Migeotte I.; Haerynck F.; Soler-Palacin P.; Martin-Nalda A.; Colobran R.; Morange P.E.; Keles S.; Coelkesen F.; Ozcelik T.; Yasar K.K.; Senoglu S.; Karabela S.N.; Rodriguez-Gallego C.; Novelli G.; Hraiech S.; Tandjaoui-Lambiotte Y.; Duval X.; Laouenan C.; Snow A.L.; Dalgard C.L.; Milner J.D.; Vinh D.C.; Mogensen T.H.; Marr N.; Spaan A.N.; Boisson B.; Boisson-Dupuis S.; Bustamante J.; Puel A.; Ciancanelli M.J.; Meyts I.; Maniatis T.; Soumelis V.; Amara A.; Nussenzweig M.; Garcia-Sastre A.; Krammer F.; Pujol A.; Duffy D.; Lifton R.P.; Zhang S.Y.; Gorochov G.; Beziat V.; Jouanguy E.; Sancho-Shimizu V.; Rice C.M.; Abel L.; Notarangelo L.D.; Cobat A.; Su H.C.; Casanova J.L.;
Science 370:0-0(2020)
Cited for: VARIANTS ILE-4; CYS-60; GLN-71; MET-80; THR-111; ARG-141 DEL; MET-157; LEU-186; LEU-302; ILE-377; PRO-386; LYS-392; ASN-465; ASN-557; LEU-595; TRP-598 AND ARG-702; CHARACTERIZATION OF VARIANTS ILE-4; CYS-60; GLN-71; MET-80; THR-111; ARG-141 DEL; MET-157; LEU-186; LEU-302; ILE-377; PRO-386; LYS-392; ASN-465; ASN-557; LEU-595; TRP-598 AND ARG-702;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.